Meningococcal Polysaccharide Vaccine MPSV4

Meningococcal Polysaccharide Vaccine MPSV4 Brand Names

Meningovax AC | Menomune A/C/Y/W-135

What is Meningococcal Polysaccharide Vaccine MPSV4

Meningococcal polysaccharide vaccine (Menomune) is administered subcutaneously for the prevention of disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135.

The vaccine is >= 85% effective at preventing infections caused by these N. meningitidis serogroups, and the immune responses produced by Menomune are similar to those observed with the intramuscularly administered meningococcal conjugate vaccines (Menactra and Menveo).

However, because the conjugate vaccines are expected to provide a longer duration of immunity towards meningococcal disease, they have largely replaced the use of Menomune as the preferred vaccine for younger adults, adolescents, children and select infants in noted risk groups.

Menomune remains the preferred vaccine for adults 56 years and older, as it is only licensed meningococcal vaccine product approved for use in this population.

Specifically, the Advisory Committee on Immunization Practices (ACIP) recommends Menomune as the preferred meningococcal vaccine for vaccine-naive persons >= 56 years if only a single dose is anticipated (e.g., travels to epidemic areas and during community outbreaks).

However, if multiple doses are anticipated or if the person was previously vaccinated with a meningococcal conjugate vaccine, the ACIP recommends individuals >= 56 years receive either Menactra or Menveo.

The meningococcal polysaccharide vaccine was initially approved by the FDA in 1978.

Indications

  • meningococcal infection prophylaxis

Side Effects

  1. angioedema
  2. anorexia
  3. arthralgia
  4. asthenia
  5. chills
  6. diarrhea
  7. dizziness
  8. drowsiness
  9. dyspnea
  10. erythema
  11. fatigue
  12. fever
  13. Guillain-Barre syndrome
  14. headache
  15. injection site reaction
  16. irritability
  17. malaise
  18. nausea
  19. paresthesias
  20. pruritus
  21. rash
  22. urticaria
  23. vomiting

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • agammaglobulinemia
  • breast-feeding
  • children
  • corticosteroid therapy
  • fever
  • Guillain-Barre syndrome
  • human immunodeficiency virus (HIV) infection
  • hypogammaglobulinemia
  • immunosuppression
  • infants
  • infection
  • intramuscular administration
  • intravenous administration
  • latex hypersensitivity
  • neonates
  • neoplastic disease
  • pregnancy
  • radiation therapy
  • severe combined immunodeficiency (SCID)
  • thimerosal hypersensitivity

Interactions

  • Ocrelizumab
  • Siponimod